© 2021 MJH Life Sciences™ and Chief Healthcare Executive. All rights reserved.
The Effects of COVID-19 on Patient Experience and Price Transparency
Mary Caffrey is the Associate Editorial Director of AJMC/Managed Care for MJH Life Sciences. Her editorial responsibilities include Evidence-Based Oncology, Chief Healthcare Executive, and Managed Healthcare Executive.
Ogi Kwon, of R1 Revenue Cycle Management (RCM) offers insights on lessons learned from the COVID-19 pandemic and the future of price transparency.
The COVID-19 pandemic provides an opportunity for organizations to think about how they can be proactive and monitor new regulatory changes in real time, said Ogi Kwon, a manager in the regulatory team at R1 RCM's advisory and assurance department.
In this interview with Chief Healthcare Executive™, Kwon explains how he feels price transparency as a whole while be something that continues to be iterated upon going forward and how requirements could take different forms.
R1 RCM is a revenue cycle management company that offers technology-driven solutions to transform health care providers' patient experience and financial performance.